Cargando…
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
The prodrug capecitabine (Xeloda) has been an important drug for treatment for gastrointestinal cancer (GI-cancer). This study explores the efficacy of continuous metronomic Xeloda, as well as tolerability and best response during treatment. Patients (n = 35) with stage IV GI-cancer were included in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933740/ https://www.ncbi.nlm.nih.gov/pubmed/24510794 http://dx.doi.org/10.1007/s12032-014-0870-2 |
_version_ | 1782304981906358272 |
---|---|
author | Miger, Jasmine Holmqvist, Annika Sun, Xiao-Feng Albertsson, Maria |
author_facet | Miger, Jasmine Holmqvist, Annika Sun, Xiao-Feng Albertsson, Maria |
author_sort | Miger, Jasmine |
collection | PubMed |
description | The prodrug capecitabine (Xeloda) has been an important drug for treatment for gastrointestinal cancer (GI-cancer). This study explores the efficacy of continuous metronomic Xeloda, as well as tolerability and best response during treatment. Patients (n = 35) with stage IV GI-cancer were included in the study and were divided into two groups; upper (n = 13) and lower (n = 22) GI-cancer. All patients were given continuous metronomic Xeloda (500 mg × 2). Best response was measured by radiological and clinical examination including laboratory results. Standard RECIST criteria were used. Median age was 66 (range 29–86). Those patients who received first and second line had the longest duration of treatment. For patients with metastatic gastrointestinal cancer, metronomic capecitabine (Xeloda) may be beneficial both as far as tumor control and quality of life is concerned. In this pilot study, palliation for more than 2 years is observed for 6 of the 35 patients. |
format | Online Article Text |
id | pubmed-3933740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-39337402014-03-03 Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer Miger, Jasmine Holmqvist, Annika Sun, Xiao-Feng Albertsson, Maria Med Oncol Original Paper The prodrug capecitabine (Xeloda) has been an important drug for treatment for gastrointestinal cancer (GI-cancer). This study explores the efficacy of continuous metronomic Xeloda, as well as tolerability and best response during treatment. Patients (n = 35) with stage IV GI-cancer were included in the study and were divided into two groups; upper (n = 13) and lower (n = 22) GI-cancer. All patients were given continuous metronomic Xeloda (500 mg × 2). Best response was measured by radiological and clinical examination including laboratory results. Standard RECIST criteria were used. Median age was 66 (range 29–86). Those patients who received first and second line had the longest duration of treatment. For patients with metastatic gastrointestinal cancer, metronomic capecitabine (Xeloda) may be beneficial both as far as tumor control and quality of life is concerned. In this pilot study, palliation for more than 2 years is observed for 6 of the 35 patients. Springer US 2014-02-08 2014 /pmc/articles/PMC3933740/ /pubmed/24510794 http://dx.doi.org/10.1007/s12032-014-0870-2 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Paper Miger, Jasmine Holmqvist, Annika Sun, Xiao-Feng Albertsson, Maria Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer |
title | Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer |
title_full | Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer |
title_fullStr | Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer |
title_full_unstemmed | Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer |
title_short | Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer |
title_sort | low-dose capecitabine (xeloda) for treatment for gastrointestinal cancer |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933740/ https://www.ncbi.nlm.nih.gov/pubmed/24510794 http://dx.doi.org/10.1007/s12032-014-0870-2 |
work_keys_str_mv | AT migerjasmine lowdosecapecitabinexelodafortreatmentforgastrointestinalcancer AT holmqvistannika lowdosecapecitabinexelodafortreatmentforgastrointestinalcancer AT sunxiaofeng lowdosecapecitabinexelodafortreatmentforgastrointestinalcancer AT albertssonmaria lowdosecapecitabinexelodafortreatmentforgastrointestinalcancer |